ALB and esophageal cancer: Therefore, we conducted a single‐arm, single‐center retrospective analysis of 27 patients treated with camrelizumab combined with albumin paclitaxel and carboplatin preoperative chemotherapy and immunotherapy in our hospital, to evaluate the safety and feasibility of chemotherapy combined with immunotherapy using camrelizumab together with albumin paclitaxel and carboplatin in the real‐world setting of borderline resectable or unresectable locally advanced esophageal cancer.